Parabilis Medicines Inc (PBLS)

Parabilis Medicines Inc stock is traded at $27.88, with a volume of 922,416. It is down -8.17% in the last 24 hours and down -5.59% over the past month. Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.